Targeting the TrkB‐SH2B2 axis, in conjunction with epigenetic regulation and multimodal interventions, holds promise for disrupting the vicious cycle of smoking‐induced white matter damage and depression. The gene discussed is NTRK2; the disease is depressive disorder.